We hypothesize that HLA-A n 2402 of the B-ALL cells of the patient described here presented tumor antigen. A somatic insertion mutation occurred in exon 3 of HLA-A n 2402 resulting in the loss of expression and therefore the loss of presentation of the immunogenic tumor peptide to the immune system. This resulted in survival advantage and subsequent proliferation of the B-ALL blast clone containing HLA-A n 2402mut. Single base mutations such as the one described here are much more difficult to detect at the molecular level than haplotype loss and are only likely to be detected by DNA sequencing. The advantages of DNA sequencing are that all nucleotides within the amplified product can be analyzed and thus mutations can also be detected. Other molecular HLA typing procedures, such as amplification with sequence-specific primers (PCR-SSP) or the use of sequence-specific oligonucleotides probes (PCR-SSO), are directed to known polymorphic regions, and the assumed conserved regions and intron sequences are not analyzed. Codon 122 is not polymorphic in HLA-A and as a result it is unlikely that PCR-SSP or PCR-SSO would have detected this mutation. It is possible that HLA allele loss may be frequently missed and therefore occurs more frequently than has been previously reported. The loss of HLA allele expression has important implications for disease progression and treatment with T-cell-based therapies. In addition, these mutations will allow the development of patient-specific molecular-based assays to monitor minimal residual disease. The availability of allele-specific monoclonal antibodies and the increasing routine use of SBT will allow the extent of HLA allele loss to be determined. Hairy cell leukemia (HCL) is a chronic mature B-cell leukemia characterized by splenomegaly, pancytopenia, monocytopenia and pronounced T-cell dysfunction. This T-cell dysfunction can result in autoimmune phenomena as well as severe morbidity caused by both bacterial and viral infectious complications. These T-cell abnormalities have been the subject of study by our group for many years. A remarkable finding was that most T cells of HCL patients lack the costimulatory signal CD28. 1 Furthermore, in many HCL patients, oligoclonal T-cell populations were found with a very restricted and skewed TCRBV repertoire, 2 a phenomenon found in more B-cell malignancies, but not as pronounced as in HCL. This points to a decreased CDR3 diversity and clonogenic expansions of some T cells. Several speculations can be made about the presence and function of the oligoclonal T-cell expansions in HCL patients. Weak expression of adhesion molecules on HCL cells might result in an inadequate immune response and clonal proliferation of T cells recognizing an HCL antigen. Clonal expansions might also originate from an immune response against a persistent systemic or viral infection, which could explain the sensitivity of HCL to interferon (IFN)-alpha. Finally, given the imbalanced immune system, autoreactive T-cell expansions might develop, directed against not only the tumor cells (Spaenij-Dekking, in press), 3 but also against autologous cells of the immune system, for example, B cells, T cells, promonocytes or mature monocytes. Such autoreactivity could explain the pancytopenia with decreased amounts of normal T and B cells, the virtual absence of dendritic cells and monocytes. 4 For characterization of clonal T-cell expansions, we isolated CD3 þ cells of five different HCL patients and determined the sequences of the CDR3 region of a clonal expansion comprising 50% or more of a certain TCRBV family (n ¼ 8). The phenotype of the clonal T-cell expansions before therapy and after restoration of the TCR repertoire was determined by separating CD3 þ T-cell populations before and after INF-a therapy of the different HCL patients into CD8, CD45
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RA , CD27, CD28 and CD57 positive and negative populations by FACs sorting, and by studying the presence of cells of the clonally expanded TCRBV T cells by PCR. We found that the in vivo clonal TCRBV cells were only present in the CD8 þ , CD45RA þ , CD27 À , CD28 À and CD57 þ populations, whereas members of the different TCRBV families were present in all sorted populations. A representative example of the experiments is shown in Figure 1 . Therefore, the in vivo clonal T-cell populations in HCL patients, sometimes representing more than 50% of a specific TCRBV family, show a phenotype which has been described for CD8
þ cytotoxic effector cells 5, 6 and corresponds with other described T-cell clonal expansions. 7 Moreover, after therapy, cells of the clonal expansion were still present and retained their cytotoxic effector phenotype.
To study the function of the clonally expanded T cells, we used different strategies for isolation and expansion of in vivo clonally expanded CD8
þ TCR BV cells. From five cases, both CD4 À , TCRBV þ and CD3 þ cells were isolated from peripheral blood mononuclear cells (PBMCs) during active disease. The presence of the clonally expanded TCRBV cells could be demonstrated in the cDNA from both sorted populations using a clone-specific PCR. However, despite different cloning strategies, we did not succeed in the isolation and expansion of CD8 þ clonal effector T cells in any of the HCL patients, either due to a low frequency of memory cells or due to their low proliferative capacity. 8 Therefore, for functional experiments, we used the PBMCs of two HCL patients enriched for in vivo CD8 þ clonal TCRBV. FACs analysis of the enriched cell populations showed that we had succeeded in preparing subsets consisting of 20-46% CD8 þ , CD28 À , CD27 À and CD57 þ T cells, of which 43-50% were positive for either TCRBV17 or TCRBV2.
We studied the possible function of the in vivo clonal T-cell populations by proliferation and cytotoxicity experiments on target cells usually present in the circulation of HCL. We focused on (a) T cells, since both the number is decreased and gaps are present in the TCRBV repertoire; 4 (b) precursor monocytes (CD33) and mature monocytes (CD14 þ /CD45 þ ), because of the extremely low numbers of monocytes and the virtual absence of dendritic cells; (c) hematopoietic stem cells (CD34 þ ) explaining the pancytopenia and bone marrow hypoplasia often seen in HCL patients; and (d) finally, since we demonstrated the presence of autologous HCL-specific T cells, 9 also HCL (CD103 þ ) cells. Target cells for proliferation and cytotoxicity experiments were isolated from either the autologous HCL patients (T cells ¼ CD3, B cells ¼ CD19, HCL cells ¼ CD103) or, when the numbers were too low in the patient, from an HLA class I-matched donor (mature mono-
In these experiments, the hematopoietic progenitor cells (CD34 þ ) were used both directly after isolation from the bone marrow mononuclear cells and after 6 days of differentiation in progenitor cell culture medium. As effector cells, subset T cells were used enriched for the appropriate TCRBV clonal population (see before). To our disappointment, neither in the proliferation nor in the cytotoxicity experiments the population enriched for the in vivo clonally expanded CD8 þ effector cells showed any reactivity to the target cells tested (Table 1) . The effect of the enriched effector cell populations on growth and differentiation of hematopoietic progenitor cells was studied by two different methods. CD34 þ cells were mixed in different ratios with the enriched T-cell populations and cocultured with and without preincubation for 7 days in semisolid medium; next, the erythroid colonies (BFU-E and CFU-E), granulocyticmacrophage colonies (CFU-GM) and pluripotent mixed colonies (CFU-GEM) were scored. Moreover, CD34 þ cells were mixed in different ratios with irradiated enriched T-cell populations, and inhibition of proliferation of CD34 þ cells was analyzed. Also, in these experiments, no effect of the circulating clonal T-cell populations was found on the growth and differentiation of hematopoietic progenitor cells (Table 1) .
Since no specific effector function of the circulating clonally expanded CD8
þ cytotoxic effector T cells against the most obvious target cell types affected in HCL could be demonstrated, we have to conclude that the cells must be directed against still unknown targets present in HCL patients.
A potential role for PRDM12 in the pathogenesis of chronic myeloid leukaemia with derivative chromosome 9 deletion Chronic myeloid leukaemia (CML) is a clonal haematopoeic stem cell disorder associated with the BCR-ABL fusion gene, generated by the Philadelphia (Ph) translocation t(9;22)(q34;q11). Recently, it was established that deletions of over 300 kb occur on the derivative chromosome 9 [der (9) ] in approximately 15% of CML patients. 1 The deletions, detected by fluorescent in situ hybridisation (FISH) using large commercial contig probes, were associated with rapid progression to blast crisis and short survival. A recent study by Kolomietz et al 2 used quantitative PCR to demonstrate that a further subset of der (9) deletions exist beyond the resolution of large commercial FISH probes. Subsequent mapping of the microdeletions identified a minimal commonly deleted region (CDR) of 120 kb, associated with short survival. The CDR, immediately 5 0 to ABL, contained two known genes, the ribosomal RNA processing protein 4 (RRP4) and the positive regulatory (PR)-domain zinc-finger protein 12 (PRDM12). The latter gene is a member of the closely related PR-domain-containing zinc-finger family, which appear to function as negative regulators of oncogenesis and include the tumour-associated genes MDS1-EVI1, RIZ, BLIMP1, MEL1 and PFM1.
3-7 PRDM12 therefore represents an attractive candidate tumour suppressor gene within the der(9) CDR.
We report a case of CML with short survival but no overt der(9) deletion, in which FISH identified a novel cryptic insertion of chromosome 9 sequences into chromosome 7. Detailed mapping of the extent of the insertion revealed that the distal breakpoint had occurred within a 70 kb region containing the PRMD12 gene. Our findings suggest that disruption of PRMD12 may account for the observed short survival of this patient and further support a role for this gene in the pathogenesis of CML patients with der(9) deletions.
The patient, who survived for 24 months after initial diagnosis had an apparent classical Ph translocation t(9;22)(q34;q11) as the sole cytogenetic abnormality. Application of a dual-fusion BCR-ABL FISH system to the patient's bone marrow (BM) metaphase cells revealed a BCR-ABL fusion on the Ph chromosome as expected; however, the components of the second fusion were unexpectedly separated, with the red 3 0 BCR component remaining present on the der(9), while the green 5 0 ABL fragment was visible on a C-group chromosome. This chromosome was identified by reverse DAPI banding as
